选择性deubiquitinaseUSP30抑制的结构前提是由小分子硫胺胺的抑制
Darragh P O'Brien1, Hannah B L Jones1, Franziska Guenther2
1Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, Oxfordshire, UK.
Molecular & cellular proteomics : MCP
|June 29, 2023
概括
抑制线粒体酶Ubiquitin特定蛋白酶30 (USP30) 可能治疗神经退行性疾病,如帕金森病. 研究人员阐明了小分子抑制剂如何与USP30结合,揭示了其未来药物开发的机制.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 神经科学是一个神经科学.
背景情况:
- 线粒体功能障碍和线粒体功能障碍与神经退行性疾病有关,包括帕金森病.
- 乌比基特异蛋白酶30 (USP30) 是一种关键的线粒体二基化酶,其抑制是一种潜在的治疗策略.
- 了解USP30抑制剂的精确结合机制对于开发有效治疗方法至关重要.
研究的目的:
- 为了研究一种基于硫胺的小分子USP30抑制的分子机制,USP30inh.
- 描述USP30抑制的结合动力学和结构基础.
- 为下一代USP30抑制剂的合理设计提供见解.
主要方法:
- 基于活动的蛋白质分析质谱法 (ABPP-MS) 来评估目标参与和选择性.
- 在体外酶动力学试验中测试以确定结合行为.
- -交换质谱 (HDX-MS) 与计算对接相结合,以阐明复杂的结构.
主要成果:
- USP30inh显示出USP30的强大和选择性抑制,有效地吸引了目标.
- 酶动力学揭示了USP30inh的缓慢和紧密结合,这是强抑制的特征.
- 结构分析发现USP30inh在指-手掌裂内结合,遮住活性部位并防止基质访问.
结论:
- USP30inh通过与USP30的关键裂结合,从而阻止其二化活性,作为一种强有力的抑制剂.
- 阐明的结合机制为设计针对USP30进行神经退行性疾病治疗的改进抑制剂提供了基础.
- 这些发现促进了对线粒体质量控制和疾病背景下USP30功能和抑制的理解.
相关概念视频
Covalently Linked Protein Regulators
6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.9K
The Proteasome
907
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
907
Drug Metabolism: Phase II Reactions
3.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K
Electrophilic Aromatic Substitution: Sulfonation of Benzene
6.2K
Sulfonation of benzene is a reaction wherein benzene is treated with fuming sulfuric acid at room temperature to produce benzenesulfonic acid. Fuming sulfuric acid is a mixture of sulfur trioxide and concentrated sulfuric acid.
6.2K
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


